Randomized phase II study of carboplatin + paclitaxel + bevacizumab or cisplatin + pemetrexed + bevacizumab in patients with previously untreated locally advanced or metastatic non-squamous non-small cell lung cancer (CLEAR study)
Phase of Trial: Phase II
Latest Information Update: 27 Aug 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CLEAR
- 26 Aug 2019 Status changed from active, no longer recruiting to completed.
- 12 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 20 Mar 2014 New trial record